Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02855411 · ClinicalTrials.gov registry record · Phase 2
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02855411 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 35 participants.
The verdict
NCT02855411, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether PF-04958242 is safe and effective in the treatment of cognitive dysfunction in schizophrenia subjects
Interventions
- DRUG placebo
- DRUG PF-04958242
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-08-29 |
| Est. Completion | 2016-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02855411
The ClinicalTrials.gov registry entry for NCT02855411 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02855411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02855411 about?
NCT02855411 is a clinical study titled "A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)". The purpose of this study is to determine whether PF-04958242 is safe and effective in the treatment of cognitive dysfunction in schizophrenia subjects
What is the current status of trial NCT02855411?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2016-08-29. Estimated completion is 2016-09-26.
What interventions are being tested in trial NCT02855411?
The interventions under investigation include: placebo (DRUG), PF-04958242 (DRUG).
Who is sponsoring clinical trial NCT02855411?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.